From professional translators, enterprises, web pages and freely available translation repositories.
bisphosphonates act by inhibiting osteoclast activity, although the precise mechanism is still not clear.
bisfosfonater virker ved en hæmning af osteoklast- aktiviteten, men virkningsmekanismen er endnu ikke fuldt ud klarlagt.
ibandronic acid selectively inhibits osteoclast activity, reducing bone resorption and thereby reducing skeletal complications of the malignant disease.
ibandronsyre hæmmer selektivt osteoklastaktiviteten, reducerer knogleresorptionen og mindsker herved skeletkomplikationerne ved den maligne sygdom.
the main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase, but this does not exclude other mechanisms.
zoledronsyres molekylære hovedmål i osteoklasterne er enzymet farnesyl pyrofosfat syntase, men dette udelukker ikke andre mekanismer.
giant cell tumours of bone are characterized by neoplastic stromal cells expressing rank ligand and osteoclast-like giant cells expressing rank.
kæmpecelletumorer i knogle er kendetegnet ved neoplastiske stromalceller, der udtrykker rank-liganden, og osteoklast-lignende kæmpeceller, der udtrykker rank.
data from in vitro, ex-vivo, and animal models with bortezomib suggest that it increases osteoblast differentiation and activity and inhibits osteoclast function.
data fra forsøg in vitro, ex vivo og i dyremodeller med bortezomib tyder på, at bortezomib øger osteoblastdifferentieringen og -aktiviteten og hæmmer osteoklastfunktionen.